Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE DTPA versus NEPHROFLOW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE DTPA versus NEPHROFLOW.
DRAXIMAGE DTPA vs NEPHROFLOW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
NEPHROFLOW is a vasodilator that increases renal blood flow by selectively dilating afferent arterioles, leading to enhanced glomerular filtration rate (GFR). It also inhibits sodium reabsorption in the proximal tubule, promoting diuresis.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
NEPHROFLOW (Ioversol) 350 mg iodine/mL: 1 mL/kg intravenously up to 150 mL maximum for contrast imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
4.2 hours (terminal) in normal renal function; prolongs in CKD.
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Primarily renal (85% unchanged); 15% biliary/fecal. In renal impairment, half-life doubles.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical